Transformational Cancer Treatment
At Kite, we are focused on the cure. Our singular focus is on cell therapy — the use of genetically modified immune cells programmed to target tumors — which we believe has the potential to change the way cancer is treated.
Through our focused efforts and important industry and academic partnerships we have been able to advance our industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates with the goal of treating both hematological cancers and solid tumors.
After learning that two lines of chemotherapy to treat his diffuse large B-cell lymphoma (DLBCL) had failed, Shon and his wife, Lisa, were devastated. In that moment, they felt defeated, like they had exhausted all of their options in their battle against cancer.
But Shon didn’t give up hope. "What’s my weapon? What’s in my toolbox?" he remembers asking. When he heard about CAR T cell therapy from his oncologist, he was intrigued and wanted to learn more. With CAR T, he was excited to discover an option that takes his own T cells and engineers them to fight the cancer cells in his body.
After talking to his doctor, Shon and his wife made the decision to try CAR T. Throughout their journey with cancer, hope remained the common theme that helped Shon and Lisa maintain a positive attitude and stay optimistic about life. "When you have cancer, it's a game of percentages," said Shon. "It's not so much the odds you're looking for, it's the hope."
Not all patients will experience the same results. Featured patient compensated by Kite.
"We are dedicated to pursuing cell therapy to fundamentally change health outcomes in cancer, and to ensuring medicines are made available to all patients who may be helped by them, regardless of location or cost."
– Christi Shaw, Chief Executive Officer, Kite
We envision a world in which people have the treatment options they need to help live the lives they want. We are dedicated to doing all we can to reach that future together.